HealthLinx Limited (ASX:HTX), has reached an agreement with The University of Liverpool (UK) to in-license additional patented biomarker technology and antibodies that has shown efficacy in detecting grade I & II ovarian cancer. HealthLinx and The University of Liverpool (UK) have been jointly developing this technology over the past twelve months which has potential to be the world’s first commercially available, multi-marker early stage ovarian cancer diagnostic. [click link for full article]

More: continued here

This entry was posted on Sunday, December 2nd, 2007 at 4:12 am and is filed under Cervical Cancer. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.